Follow
David Preiss
David Preiss
Associate Professor, University of Oxford
Verified email at ndph.ox.ac.uk - Homepage
Title
Cited by
Cited by
Year
Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials
N Sattar, D Preiss, HM Murray, P Welsh, BM Buckley, AJM de Craen, ...
The Lancet 375 (9716), 735-742, 2010
30312010
Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis
D Preiss, SRK Seshasai, P Welsh, SA Murphy, JE Ho, DD Waters, ...
Jama 305 (24), 2556-2564, 2011
17742011
Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials
KK Ray, SRK Seshasai, S Wijesuriya, R Sivakumaran, S Nethercott, ...
The Lancet 373 (9677), 1765-1772, 2009
17732009
Interpretation of the evidence for the efficacy and safety of statin therapy
R Collins, C Reith, J Emberson, J Armitage, C Baigent, L Blackwell, ...
The Lancet 388 (10059), 2532-2561, 2016
17382016
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
SL Kristensen, R RÝrth, PS Jhund, KF Docherty, N Sattar, D Preiss, ...
The lancet Diabetes & endocrinology 7 (10), 776-785, 2019
9892019
HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials
DI Swerdlow, D Preiss, KB Kuchenbaecker, MV Holmes, JEL Engmann, ...
The Lancet 385 (9965), 351-361, 2015
6852015
Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials
J Armitage, C Baigent, E Barnes, DJ Betteridge, L Blackwell, M Blazing, ...
The Lancet 393 (10170), 407-415, 2019
5332019
Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial
SE Nissen, E Stroes, RE Dent-Acosta, RS Rosenson, SJ Lehman, ...
Jama 315 (15), 1580-1590, 2016
5152016
Statin safety and associated adverse events: a scientific statement from the American Heart Association
CB Newman, D Preiss, JA Tobert, TA Jacobson, RL Page, LB Goldstein, ...
Arteriosclerosis, thrombosis, and vascular biology 39 (2), e38-e81, 2019
4782019
Non-alcoholic fatty liver disease: an overview of prevalence, diagnosis, pathogenesis and treatment considerations
D Preiss, N Sattar
Clinical science 115 (5), 141-150, 2008
4122008
Liver enzymes, nonalcoholic fatty liver disease, and incident cardiovascular disease: a narrative review and clinical perspective of prospective data
N Ghouri, D Preiss, N Sattar
Hepatology 52 (3), 1156-1161, 2010
3932010
Non-alcoholic fatty liver disease
N Sattar, E Forrest, D Preiss
Bmj 349, 2014
3572014
PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study
AF Schmidt, DI Swerdlow, MV Holmes, RS Patel, Z Fairhurst-Hunter, ...
The lancet Diabetes & endocrinology 5 (2), 97-105, 2017
3562017
Risk related to pre–diabetes mellitus and diabetes mellitus in heart failure with reduced ejection fraction: insights from prospective comparison of ARNI With ACEI to determine†…
SL Kristensen, D Preiss, PS Jhund, I Squire, JS Cardoso, B Merkely, ...
Circulation: Heart Failure 9 (1), e002560, 2016
3362016
SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?
N Sattar, J McLaren, SL Kristensen, D Preiss, JJ McMurray
Diabetologia 59, 1333-1339, 2016
3182016
GDF15 mediates the effects of metformin on body weight and energy balance
AP Coll, M Chen, P Taskar, D Rimmington, S Patel, JA Tadross, I Cimino, ...
Nature 578 (7795), 444-448, 2020
2952020
Association of lipid fractions with risks for coronary artery disease and diabetes
J White, DI Swerdlow, D Preiss, Z Fairhurst-Hunter, BJ Keating, ...
JAMA cardiology 1 (6), 692-699, 2016
2612016
The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study
WG Herrington, D Preiss, R Haynes, M von Eynatten, N Staplin, ...
Clinical kidney journal 11 (6), 749-761, 2018
2242018
Lipid-modifying therapies and risk of pancreatitis: a meta-analysis
D Preiss, MJ Tikkanen, P Welsh, I Ford, LC Lovato, MB Elam, JC LaRosa, ...
Jama 308 (8), 804-811, 2012
2152012
Empagliflozin in patients with chronic kidney disease
EMPA-Kidney Collaborative Group
New England Journal of Medicine 388 (2), 117-127, 2023
2072023
The system can't perform the operation now. Try again later.
Articles 1–20